Fluoxetine alters the effects of intravenous cocaine in humans
Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study evaluated the pharmacologic interaction between fluoxetine and cocaine in healthy adult male volunteers (N = 5) with histories of cocaine abuse....
Saved in:
Published in | Journal of clinical psychopharmacology Vol. 14; no. 6; p. 396 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.12.1994
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study evaluated the pharmacologic interaction between fluoxetine and cocaine in healthy adult male volunteers (N = 5) with histories of cocaine abuse. Oral capsules were administered daily containing either placebo (weeks 1 and 4) or fluoxetine in a series of ascending doses (10, 20, 30, and 40 mg) where each dose was given for three to four consecutive days. Cocaine challenge sessions were conducted twice weekly, once at each active dose level and twice during both the placebo and washout phases. Subjects received three ascending intravenous doses of cocaine (0, 20, and 40 mg) 1.5 hours apart and were monitored on physiologic and subjective measures. Cocaine alone increased heart rate, blood pressure, and pupillary diameter and increased subjective reports reflecting positive mood effects and drug liking. Fluoxetine (40 mg) significantly decreased subjective ratings of cocaine's positive mood effects on several visual analog measures. Fluoxetine also attenuated the mydriatic effect of cocaine. No adverse physiologic interactions between the two drugs were observed on cardiovascular measures. These data suggest that fluoxetine may be safely used in the presence of cocaine use and should be investigated further as a potential pharmacotherapy for cocaine abuse. |
---|---|
AbstractList | Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study evaluated the pharmacologic interaction between fluoxetine and cocaine in healthy adult male volunteers (N = 5) with histories of cocaine abuse. Oral capsules were administered daily containing either placebo (weeks 1 and 4) or fluoxetine in a series of ascending doses (10, 20, 30, and 40 mg) where each dose was given for three to four consecutive days. Cocaine challenge sessions were conducted twice weekly, once at each active dose level and twice during both the placebo and washout phases. Subjects received three ascending intravenous doses of cocaine (0, 20, and 40 mg) 1.5 hours apart and were monitored on physiologic and subjective measures. Cocaine alone increased heart rate, blood pressure, and pupillary diameter and increased subjective reports reflecting positive mood effects and drug liking. Fluoxetine (40 mg) significantly decreased subjective ratings of cocaine's positive mood effects on several visual analog measures. Fluoxetine also attenuated the mydriatic effect of cocaine. No adverse physiologic interactions between the two drugs were observed on cardiovascular measures. These data suggest that fluoxetine may be safely used in the presence of cocaine use and should be investigated further as a potential pharmacotherapy for cocaine abuse. |
Author | Sullivan, J T Fromme, R Bigelow, G E Walsh, S L Preston, K L |
Author_xml | – sequence: 1 givenname: S L surname: Walsh fullname: Walsh, S L organization: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224 – sequence: 2 givenname: K L surname: Preston fullname: Preston, K L – sequence: 3 givenname: J T surname: Sullivan fullname: Sullivan, J T – sequence: 4 givenname: R surname: Fromme fullname: Fromme, R – sequence: 5 givenname: G E surname: Bigelow fullname: Bigelow, G E |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/7884020$$D View this record in MEDLINE/PubMed |
BookMark | eNotT11LwzAUzcNkbtOfIOQPRJP0tul9EWQ4FQa-6PNI0htWadPRpKL_3g53Xs4H9x44a7aIQyTGuJL3SqJ5kDPAKBAKEZSenThH5YKtpDZKSAN4zdYpfUmpwOhyyZamrkFquWKPu24afii3kbjtMo2J5yNxCoF8TnwIvI15tN8UhylxP3h7vmwjP069jemGXQXbJbq98IZ97p4_tq9i__7ytn3aC18UmEWAylGtLFFj0M26Kr0zWCkKJGuNANoCegOk0WJpnCwIGghqfi8aB3rD7v57T5PrqTmcxra34-_hskP_Ac8uS84 |
CitedBy_id | crossref_primary_10_1016_S0740_5472_99_00076_8 crossref_primary_10_1016_j_pbb_2003_08_013 crossref_primary_10_1016_S0376_8716_02_00104_7 crossref_primary_10_1016_0376_8716_96_01233_1 crossref_primary_10_1523_JNEUROSCI_18_23_10078_1998 crossref_primary_10_1016_S0014_2999_96_00856_4 crossref_primary_10_1016_0376_8716_95_01173_2 crossref_primary_10_1111_j_1471_4159_2006_04163_x crossref_primary_10_1017_S146114571300059X crossref_primary_10_1111_j_1521_0391_1998_tb00329_x crossref_primary_10_1080_10550490490512753 crossref_primary_10_1016_j_psc_2012_03_011 crossref_primary_10_1016_S0091_3057_01_00764_X crossref_primary_10_1002_hup_1055 crossref_primary_10_1016_0028_3908_95_00166_2 crossref_primary_10_1016_j_bcp_2007_08_003 crossref_primary_10_1016_S0376_8716_98_00032_5 crossref_primary_10_1016_0014_2999_95_00280_X crossref_primary_10_1016_0376_8716_95_01137_N crossref_primary_10_1037_1064_1297_11_2_123 crossref_primary_10_1124_jpet_111_186981 crossref_primary_10_1016_j_nic_2007_07_004 crossref_primary_10_1016_j_pnpbp_2013_11_013 crossref_primary_10_1016_S0169_328X_98_00226_5 crossref_primary_10_1016_j_bbr_2014_04_007 crossref_primary_10_1016_S0376_8716_98_00185_9 crossref_primary_10_1021_acs_jctc_2c00002 crossref_primary_10_1177_0269881118805488 crossref_primary_10_1016_S0149_7634_02_00017_9 crossref_primary_10_1111_j_1521_0391_1996_tb00318_x crossref_primary_10_1016_j_drugalcdep_2006_08_016 crossref_primary_10_1080_00450618_2016_1264479 crossref_primary_10_1016_j_drugalcdep_2014_05_008 crossref_primary_10_1016_j_heliyon_2024_e29979 crossref_primary_10_1111_j_1369_1600_2007_00061_x crossref_primary_10_1016_j_neuropharm_2013_06_030 crossref_primary_10_1016_S0376_8716_00_00198_8 crossref_primary_10_3109_15563650_2016_1142090 crossref_primary_10_1111_j_1360_0443_2005_00987_x crossref_primary_10_1016_j_pbb_2003_07_004 crossref_primary_10_1016_S0740_5472_97_00018_4 crossref_primary_10_1016_S0165_1781_98_00048_1 crossref_primary_10_1016_S0091_3057_96_00436_4 crossref_primary_10_1124_pr_114_009514 crossref_primary_10_1016_S0376_8716_98_00164_1 crossref_primary_10_1016_j_pbb_2005_10_013 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/00004714-199412000-00005 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 7884020 |
Genre | Clinical Trial Randomized Controlled Trial Journal Article |
GroupedDBID | --- .-D .3C .GJ .Z2 01R 0R~ 1CY 1J1 3O- 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ 8L- AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AAQQT AARTV AASCR AASOK AAXQO AAYEP ABASU ABBUW ABDIG ABIVO ABJNI ABVCZ ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFDTB AFFNX AFUWQ AGINI AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJIOK AJNWD AJNYG AJZMW AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BOYCO BQLVK BS7 C45 CGR CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ H~9 IKREB IKYAY IN~ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C N4W N9A NEJ NPM N~7 N~B N~M O9- OAG OAH OCUKA ODA OJAPA OL1 OLG OLH OLU OLV OLW OLY OLZ OMH OPC OPUJH OPX ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM YFH YOC ZFV ZGI ZXP ZY1 ZZMQN |
ID | FETCH-LOGICAL-c339t-f46be81aeed79b6be65cb7961efe0829442a49c74e29a957b03e4d4f1c333db42 |
ISSN | 0271-0749 |
IngestDate | Sat Sep 28 07:32:35 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c339t-f46be81aeed79b6be65cb7961efe0829442a49c74e29a957b03e4d4f1c333db42 |
PMID | 7884020 |
ParticipantIDs | pubmed_primary_7884020 |
PublicationCentury | 1900 |
PublicationDate | 1994-12-01 |
PublicationDateYYYYMMDD | 1994-12-01 |
PublicationDate_xml | – month: 12 year: 1994 text: 1994-12-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of clinical psychopharmacology |
PublicationTitleAlternate | J Clin Psychopharmacol |
PublicationYear | 1994 |
SSID | ssj0014725 |
Score | 1.786988 |
Snippet | Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 396 |
SubjectTerms | Adult Affect - drug effects Arousal - drug effects Blood Pressure - drug effects Cocaine - antagonists & inhibitors Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Fluoxetine - adverse effects Fluoxetine - therapeutic use Heart Rate - drug effects Humans Male Substance Abuse, Intravenous - rehabilitation Substance-Related Disorders - rehabilitation |
Title | Fluoxetine alters the effects of intravenous cocaine in humans |
URI | https://www.ncbi.nlm.nih.gov/pubmed/7884020 |
Volume | 14 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEF48EHwRT7zZB_HFRtzN5noRRCylYhGt0DfJJrMgaFtsFfXXO3vYjbXi8RLCLglJvo_J7Ox8M4TssVzkKpVRwJgqAgFRGaQlqABYBEzFWai4FidftOLGjWh2oo7f0TXqkqE8LN4m6kr-gyqOIa5aJfsHZEc3xQE8R3zxiAjj8VcY1--fei9aswwHZtd7MJ6icadDt8-2DCtavvzO1ggxjfkG3_ilI62kFWj1fW3ravR9YMIx1wej2LHO5XCp-Od-tLrX1PQJ2fXH3oNtz37lww6mfrBP4bDWiScsQP8j-2RKRYUyVbsY2ra1X-y1rQNsFioJEzrrRbAPsbuRYw8rMPYfDI64aNeL3h8nx-pou5lpMp2k2hS2dFjHbTeJxHTnHb2TS_n6qO456dnmyZy749iCxDgm7UWy4JCjJ5YeS2QKustk_9LC9lqjba-wG9ToPr2sALpCjj2HqOUQRQ5RxyHaU7TCIeo4hGPUcmiV3NTP2qeNwPXUCIowzIaBErGElOXoGiWZxPM4KmSSxQwUaJm1EDwXWZEI4FmeRYk8CkGUQjG8PCyl4GtkptvrwjqhKUiuYsBfgEQXh6s8PAI0CawUIWc5hw2yZr_Lbd8WTrl1H2zzu4ktMu-ptk1mFbIZdtDpG8pdA9g7QRdT3A |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fluoxetine+alters+the+effects+of+intravenous+cocaine+in+humans&rft.jtitle=Journal+of+clinical+psychopharmacology&rft.au=Walsh%2C+S+L&rft.au=Preston%2C+K+L&rft.au=Sullivan%2C+J+T&rft.au=Fromme%2C+R&rft.date=1994-12-01&rft.issn=0271-0749&rft.volume=14&rft.issue=6&rft.spage=396&rft_id=info:doi/10.1097%2F00004714-199412000-00005&rft_id=info%3Apmid%2F7884020&rft_id=info%3Apmid%2F7884020&rft.externalDocID=7884020 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0271-0749&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0271-0749&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0271-0749&client=summon |